Open Access<p>IV Tramadol – A New Treatment Option for Management of Post-Operative Pain in the US: An Open-Label, Single-Arm, Safety Trial Including Various Types of Surgery</p>
Author(s) -
Harold S. Minkowitz,
David Leiman,
Lucy Lu,
Scott A. Reines,
Michael Ryan,
Mark Harnett,
Neil Singla
Publication year - 2020
Publication title -
journal of pain research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.888
H-Index - 49
ISSN - 1178-7090
DOI - 10.2147/jpr.s251175
Subject(s) - tramadol , medicine , tolerability , adverse effect , anesthesia , opioid , analgesic , receptor
There is a need to reduce exposure to Schedule II opioids in the United States (US) due to the ongoing opioid epidemic. Schedule II opioids have higher potential for abuse and misuse than Schedule IV opioids. This Phase 3, multicenter, single-arm, open-label, multiple-dose US trial evaluated the safety and tolerability of intravenous tramadol 50 mg, a Schedule IV opioid, in the management of postoperative pain in a real-world setting, where intravenous tramadol is not yet approved for use.